Evogene, a leading computational biology company, has introduced a breakthrough technology called TargetSelector, aimed at revolutionizing target-protein discovery. This cutting-edge application streamlines the process of identifying novel targets for innovative products, offering researchers in various industries a powerful tool to expedite their work.
Proteins are integral to numerous biological processes and serve as key targets for the development of therapeutics, ag-chemicals, and other life science solutions. The challenge lies in identifying a suitable target-protein from the thousands available in a given organism. Evogene’s TargetSelector solves this problem by leveraging predictive machine learning algorithms and genomic data.
By utilizing the power of artificial intelligence (AI) and predictive biology, TargetSelector allows researchers to gain valuable insights into a particular organism’s protein requirements. It efficiently narrows down the list of potential target-proteins by considering factors such as homology, druggability, essentiality, and biological pathways. This optimization of the discovery process not only saves time and resources but also increases the likelihood of success.
Dr. Nir Arbel, Chief Product Officer at Evogene, expressed his excitement about the new addition to Evogene’s ChemPass AI tech-engine. He highlighted the broad scope that TargetSelector offers in finding optimal target-proteins for small molecules. Evogene’s subsidiary, AgPlenus, will be the first to benefit from this improvement by using TargetSelector to identify novel mechanisms of action for pesticides.
The ChemPass AI tech-engine is a computational platform specifically designed for discovering and optimizing small molecules in life-science products, including therapeutics and ag-chemicals. It combines the power of docking techniques and machine learning to accelerate the discovery process like never before.
Trained on vast repositories of molecular data and biological targets, ChemPass AI recognizes intricate patterns and complex relationships between small molecules and their target-proteins. This enables the platform to evaluate an organism’s proteome and billions of potential candidates, ranking them according to their likelihood of success. Ultimately, ChemPass AI reduces the time and resources required to identify promising target-proteins and leads.
Evogene aims to revolutionize the development of life-science-based products by utilizing cutting-edge technologies. The company operates three unique tech-engines, including MicroBoost AI, ChemPass AI, and GeneRator AI. Each tech-engine focuses on discovering and developing products based on specific core components such as microbes, small molecules, and genetic elements.
With strategic partnerships and collaborations, Evogene and its subsidiaries aim to leverage their tech-engines to develop innovative solutions. The company’s commitment to scientific excellence and technological advancement positions them to tackle pressing global challenges effectively.
The introduction of TargetSelector is a significant advancement in Evogene’s ChemPass AI tech-engine. This breakthrough technology not only expedites the discovery process but also opens doors for partnerships with industry leaders. By unlocking innovation and delivering groundbreaking solutions, Evogene strives to make a substantial impact on pharmaceuticals, agriculture, and environmental applications.
Evogene’s dedication to leveraging AI and big data to revolutionize the life-science industry sets them apart. With TargetSelector’s potential to streamline target-protein discovery, researchers and scientists can expect more efficient and successful development processes. As the world faces complex challenges, Evogene continues to pave the way for transformative solutions in various domains.
